Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vaccine delivery methods using viral vectors.

Andreas Bråve1, Karl Ljungberg, Britta Wahren

  • 1Swedish Institute for Infectious Disease Control and Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, 171 82 Stockholm, Sweden.

Molecular Pharmaceutics
|February 6, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Signs of Cross-Reactivity Between SARS-CoV-2 and Other Coronaviruses in a Pre-Vaccine Swedish School Setting.

Acta paediatrica (Oslo, Norway : 1992)·2026
Same author

High prevalence of undocumented SARS-CoV-2 infections revealed by analysis of nucleocapsid-specific IgG responses in diagnosed and undiagnosed individuals.

PLOS global public health·2025
Same author

Logistics for Rapid Isolation of Viruses From Humans.

Health security·2024
Same author

High Prevalence of SARS-CoV-2 Omicron Infection Despite High Seroprevalence, Sweden, 2022.

Emerging infectious diseases·2023
Same author

HIV-1 Protease as DNA Immunogen against Drug Resistance in HIV-1 Infection: DNA Immunization with Drug Resistant HIV-1 Protease Protects Mice from Challenge with Protease-Expressing Cells.

Cancers·2023
Same author

Rapid emergence of omicron sublineages expressing spike protein R346T.

The Lancet regional health. Europe·2022
Same journal

Dual-Targeted Radionuclide Therapy with <sup>161</sup>Tb Instigates Anticancer Immunity in "Cold" Murine Prostate Tumor.

Molecular pharmaceutics·2026
Same journal

Development of [<sup>111</sup>In]In-CHX-A″-DTPA-αCD68 for ImmunoSPECT to Image Murine Macrophages.

Molecular pharmaceutics·2026
Same journal

Mechanistic Insight into Self-Gelation Involved in Prescription Design for Optimization of Tablet Performance.

Molecular pharmaceutics·2026
Same journal

[<sup>68</sup>Ga]Ga-DOTA-DP-UBI 29-41: A Novel <sup>68</sup>Ga-Labeled Ubiquicidin 29-41 Derivative Containing d-Proline for Bacterial Infection PET Imaging.

Molecular pharmaceutics·2026
Same journal

Comparative Investigation of the Impact of Sodium Citrate Buffers on Lipid Nanoparticles of circRNA or Linear mRNA.

Molecular pharmaceutics·2026
Same journal

Preclinical Evaluation of <sup>177</sup>Lu-Labeled Anti-CLDN18.2 VHH-Fc for Radioimmunotherapy in Gastric Cancer.

Molecular pharmaceutics·2026
See all related articles

This review compares viral vectors and plasmid DNA for gene delivery, highlighting their characteristics, strengths, and limitations for vaccines and immunotherapeutics.

Area of Science:

  • * Molecular biology and virology
  • * Gene therapy and vaccine development

Background:

  • * Viral vectors are crucial for delivering genetic material for therapeutic and vaccine purposes.
  • * Understanding vector capabilities is essential for effective immunotherapeutic and vaccine design.

Purpose of the Study:

  • * To review and compare selected viral vector systems and plasmid DNA as gene delivery vehicles.
  • * To provide an overview of their specific characteristics, strengths, and limitations.

Main Methods:

  • * Literature review of viral vector systems and plasmid DNA.
  • * Analysis of vector features, entry and replication modes, and protein expression.
  • * Discussion of immunity-related challenges and vaccine strategies.

Related Experiment Videos

Main Results:

  • * Different viral vectors possess distinct capabilities and limitations for gene delivery.
  • * Factors such as preexisting and heterologous immunity significantly impact vector efficacy.
  • * Plasmid DNA offers an alternative gene delivery method with specific advantages.

Conclusions:

  • * The choice of viral vector or plasmid DNA depends on the specific application in vaccines and immunotherapeutics.
  • * A comprehensive understanding of vector biology and immunological factors is critical for successful gene therapy and vaccine development.